Biliary fibrosis and resultant cirrhosis are among the most common outcomes of chronic liver diseases. Currently, liver transplantation remains the only effective treatment. In seeking alternative therapeutic approaches, we focused on the potential use of the human amniotic membrane (AM). Indeed, AM has gained increasing importance for its antiscarring, anti-inflammatory, and wound-healing properties, as well as for the multipotent differentiation ability and immunomodulatory features of AM-derived cells. Intriguingly, we have recently demonstrated that placenta-derived cells reduce lung fibrosis in bleomycin-treated mice, and that AM patches reduce postischemic cardiac injury in rats. Hence, we have now investigated the effects of human AM on biliary fibrosis induced in rats through the bile duct ligation (BDL) procedure. A fragment of human AM was applied onto the liver surface after BDL and the effects on fibrosis establishment and progression were evaluated at different time points in comparison with fibrosis progression in control BDL rats. The degree of liver fibrosis was first assessed by the semiquantitative Knodell scoring system and, thereafter, by digital image morphometric analysis to quantify the area occupied by ductular reaction, activated myofibroblasts, and collagen deposition. We demonstrated a significant reduction in the severity of BDL-induced fibrosis in AM-treated rats. Indeed, while fibrosis progressed rapidly in control BDL rats, leading to cirrhosis within 6 weeks, AM-treated rats showed confined fibrosis at the portal/periportal area with no signs of cirrhosis, and a reduction in collagen deposition to about 50% of levels observed in control BDL rats. In addition, the AM was able to significantly slow the gradual progression of the ductular reaction and reduce, at all time points, the area occupied by activated myofibroblasts. These findings suggest that human AM, when applied as a patch onto the liver surface, might inhibit fibrosis progression in BDL-injured livers, and could protect against hepatic damage associated with fibrotic degeneration. 441 442 SANT'ANNA ET AL.
INTRODUCTION
of developing irreversible liver failure or hepatocellular carcinoma in later life (46) . Despite decades of research that has led to substantial Liver fibrosis is a common outcome of a variety of chronic liver diseases following different insults, such advances in understanding the molecular mechanisms of this disease's progression, hepatic cirrhosis remains a as viral infection, alcoholism, chemical toxicity, or metabolic and biliary disorders (23, 38) . Following repeated pathology that is difficult to treat in an effective manner unless orthotopic liver transplantation is performed injuries, the liver undergoes fibrotic remodeling characterized by an excessive accumulation of extracellular (31, 43) . However, this approach presents with several limitations of its own, such as: i) scarce availability of matrix (ECM) in the liver parenchyma that distorts the normal hepatic architecture, with the formation of scar donor livers, ii) the need to commit transplant patients to life-long toxic immunosuppression; iii) the fact that tissue encapsulating the area of injury (11). Progressive fibrosis could end in the advanced stage known as cir-many patients may be unsuitable for transplantation (35) . Therefore, alternative therapies are urgently needed. rhosis, characterized by fibrotic septa and rings of scar tissue that surround regenerative nodules of liver paren-More recently, hepatocyte transplantation has become a promising therapeutic tool for a variety of liver dis-chyma (11, 38) . Patients with cirrhosis have a high risk eases (19, 20, 51) . However, this approach is also cur- (4) and also to differentiate toward the hepatogenic lineage in vitro and in vivo (34, 52, 54) . rently limited by different factors, such as the restricted availability of liver for hepatocyte isolation, the poor On the other hand, several studies testify that transplantation of an intact AM fragment exerts anti-infam-quality of the cells obtained after the isolation procedure, the modest level of engraftment achieved in the matory and antiscarring effects reviewed in Gomes et al. . In addi-host liver after transplantation, and low cell viability, which is one of the reasons that long-term beneficial tion, more recently, preclinical studies have shown that, likely by means of paracrine mechanisms, transplanta-effects are often not observed following hepatocyte transplantation (19, 20, 32) .
tion of xenogenic and allogenenic placenta-derived cells reduces lung fibrosis in bleomycin-treated mice (9), The use of stem or progenitor cell transplantation is emerging as a potential alternative to hepatocyte trans-while application of a human AM patch onto ischemic rat hearts results in improved cardiac function (8) . Taken plantation for the treatment of liver disorders (36, 44) , and several potential sources have been identified for together, these findings suggest that transplantation of AM-derived cells and/or AM itself could be a novel the isolation of these cells (28) . For the treatment of liver fibrosis, this approach has been performed mainly therapeutic strategy to treat hepatic diseases. The purpose of this study was to evaluate the effects using bone marrow-derived mesenchymal stromal cells (MSCs), although the results that have been obtained of human AM patches on the establishment and progression of biliary-type liver fibrosis induced in rats through so far are controversial (reduction vs. enhancement of fibrosis), and open questions also remain regarding the the bile duct ligation (BDL) procedure. mechanisms involved (1, 11) . At least two possible MATERIALS AND METHODS mechanisms have been proposed for the potential thera-Animals and Experimental Groups peutic function on liver fibrosis exerted by MSCs: one implies their ability to engraft into the liver and differen-All animal experiments were carried out in accortiate towards the hepatogenic lineage, therefore particidance with current Italian and European regulations and pating in the regeneration of the endogenous parenlaws on the Use and Care of Animals for research (DL. chyma; the other possible mechanism, which seems the 116/27 January 1992). Sixty female Wistar rats (Laboramost likely, is related to the ability of MSCs to produce/ toire Elevage Janvier, France), weighing 220-250 g, activate paracrine mediators, such as IL-10, TNF-α, and were housed at controlled temperature (22 ± 2°C) with HGF, which lead to reduction of fibrosis [for a review daily exposure to a 12:12 light/dark cycle and allowed see Dai et al. (11) and Henderson and Forbes (23) ].
unlimited access to chow and water. Before any experi-Many issues remain to be addressed before stem cell mental intervention, the rats were randomly divided into therapy can be considered as a viable clinical strategy two experimental groups of 30 rats each, as follows: for such a liver disease, and among these is the need to BDL group-rats subjected to the BDL procedure and identify a source of stem cells that is safe, does not pose euthanized at 2 (n = 10), 4 (n = 10), and 6 weeks (n = 10) any risk of tumor induction and/or risk of viral infection after ligation; BDL + AM group-rats subjected to the (16), is easily accessible, provides a high cell yield, and BDL procedure and treated with human AM and euthanfor which cell procurement does not provoke ethical deized at 2 (n = 10), 4 (n = 10), and 6 (n = 10) weeks after bate (17, 32) . To this end, the human amniotic membrane ligation. (AM) represents a prime candidate as a possible source Human AM Collection of stem/progenitor cells. Cells isolated from this membrane have a stem cell phenotype: human amniotic epi-Human term placentas were obtained from caesarean sections or spontaneous deliveries with maternal consent thelial cells (hAEC) express pluripotent stem cell markers and are able to differentiate in vitro toward tissues of according to the guidelines of the Ethical Committee of the Catholic Hospital (CEIOC). Briefly, the human AM all three germ layers (33, 37, 53) , while human amniotic mesenchymal stromal cells (hAMSC), like MSCs of was manually separated from the chorionic membrane and washed extensively in phosphate-buffered saline other origins, have the capacity to differentiate towards cells of the mesodermal lineages, as well as toward tis-(PBS) (Sigma, St. Louis, MO, USA) containing 100 U/ ml penicillin and 100 µg/ml streptomycin (Lonza, Basel, sues of ectodermal and endodermal layers (39, 49, 53) .
Several findings suggest that human AM-derived Switzerland). The AM was then cut into pieces of adequate dimension (6 × 8 cm) that were stored separately cells might be useful for restoring the functionality of hepatic tissues that have been compromised by disease at room temperature, as reported by Hennerbichler et al. (24) , in 50-ml vials filled with serum-free and phenol or injury.
On one hand, there are data suggesting the potential red-free DMEM in sterile conditions, until application. The AM fragments were used within 24 h. As pre-ability of human AM-derived cells to engraft in the liver viously reported, the number and viability of cells in the slides (Menzel-Glaser, Braunsch, Germany) for immunohistochemical stainings. human AM fragments stored for 24 h were not significantly reduced compared to those seen using fresh mem-Liver Fibrosis Evaluation brane (8) .
The degree of liver fibrosis was examined semiquantitatively under a bright field Olympus microscope at Rat Model of BDL-Induced Fibrosis 100× magnification by applying the Knodell fibrosis The rats were anesthetized with 3% isoflurane. The scoring as follows (7): level 0, indicating absence of fiabdomen was shaved and disinfected with 10% povibrosis; level 1, fibrous portal expansion; level 3, bridgdone iodine and, after a midline abdominal incision, the ing fibrosis (portal-portal or portal-central vein linkcommon bile duct was exposed and ligated by double age); level 4, cirrhosis. The scoring was performed ligatures with 4-0 suture silk (Johnson & Johnson Mediblindly by a pathologist, who was not aware of the treatcal S.P.A. Rome, Italy). The first ligature was made bements of the rats. The average of the score taken from low the junction of the hepatic ducts and the second 10 nonoverlapping random fields per section was used ligature was made above the entrance of the pancreatic to generate a single score for each specimen. duct, as reported by Chen et al. (10). The common bile duct was then sectioned between the ligatures. The ab-Immunohistochemistry dominal incision was then closed in two layers with 4-0
Immunostainings for cytokeratin 19 (CK19) and αand 3-0 suture silk. Thus, animals had total, permanent smooth muscle actin (α-SMA) were performed to idenbiliary obstruction.
tify bile ductular structures and activated myofibroblasts, In animals of the AM-treated group, immediately respectively. Briefly, each section was immersed into after BDL and before closing of the abdominal wall, an the preheated target retrieval solution (W-CAP citrate AM fragment was gently placed onto the liver with its buffer pH 6.0) (BioOptica, Milano, Italy) and incubated mesenchymal side in contact with the liver surface, in for 30 min at 98°C. This solution achieves, in just one such way that the whole surface of the liver lobules was step, deparaffinization and heat-induced epitope recovered. Holding its upper extremities using two fortrieval. Endogenous peroxidase activity was blocked ceps, the membrane was inserted under the liver and, with 3% hydrogen peroxide for 10 min followed by with gentle movements, it was then cranially shifted and three washes in PBS containing 0.05% Tween 20 raised until it covered the surface of the median lobe.
(Sigma). Sections were then incubated overnight in a The inferior membrane extremities were also raised in humidity chamber at 4°C with primary mouse monoorder to cover the remaining liver lobes and, finally, the clonal antibodies against human α-SMA (Clone 1A4, superior and the inferior membrane extremities were dilution 1:600, Dako Corporation, Denmark), which attached to each other with a drop of methacrylate glue cross-reacts with the rat antigen α-SMA (48), and to keep the membrane in place on the liver, avoiding its against CK19 (Clone-b170, dilution 1:100, Novocastra, dispersion into the peritoneal cavity. After this proce-Newcastle, UK) (45) . Sections were again washed, and dure, the abdomen was closed, as described above for incubated with secondary antibody using the MACH 4 TM animals of the BDL group. After surgery, each rat was Universal HRP-polymer kit (Biocare Medical, Concord, given subcutaneous antibiotic therapy (Marbocyl 1%, 10 CA, USA) according to the manufacturer's instructions. mg/kg) and following the recommendations of Beck and For visualization, diaminobenzidine (BioGenex Labora-Lee (6) , subcutaneous injection of vitamin K (5 mg/kg) tories, San Remon, CA) was applied for 5 min. All secwas administered weekly to decrease mortality from tions were counterstained with hematoxylin, dehydrated hemorrhagic diathesis.
in alcohol, cleared in xylene, and mounted with Eukitt Mounting Medium TM (Fluka Biochemika, Steinheim, Liver Explants and Histological Processing Germany). Slides were then air dried. The specificity of the antibody-antigen reaction was tested by replacing Two, 4, and 6 weeks after BDL, 10 animals of each group were euthanized with an excess of isoflurane.
the primary antibodies with normal serum from the donor species of the first antibody (mouse IgG2a, Dako Liver samples were taken from the major left and median lobes (which comprise approximately 70% of the Corporation, Denmark). As an internal control, vascular smooth muscle and bile duct immunoreactivity were as-liver), fixed in 10% neutral buffered formalin (for at least 48 h), and embedded in paraffin. At least four 4-sessed for α-SMA and CK19, respectively. µm-thick sections were used from each rat and these Image Morphometric Analysis were stained with hematoxylin/eosin and with Goldner's modified Masson trichrome staining procedure for fibro-Goldner's modified Masson trichrome staining, CK19 and α-SMA immunostainings were quantitatively evalu-sis and collagen analysis, or placed on polysine-L-coated ated by digital image analysis. The quantification was nation of rat liver tissues that had been subjected to Goldner's modified Masson trichrome staining. This method performed using the open-source CellProfiler image analysis software (27) . The images of all stainings were allows a staging of fibrotic and cirrhotic liver lesions, by considering not only the extent of ECM deposition captured by a digital camera (Olympus Camedia C-4040 ZOOM) and digitalized at 1024 × 768 pixel, 24 bit/pixel (i.e., collagen deposition) but also the progressive expansion of the lesions from portal regions to gradually resolution with a global magnification of 100×. The digital images were processed by CellProfiler, to identify, involving the interstitial parenchyma, and finally resulting in liver remodeling. isolate, and measure areas occupied by immunostained cells or by collagen deposition over the total liver paren-After BDL induction, the onset of the fibrotic injury is mainly characterized by periductular collagen deposits chyma area.
The mean value taken from 10 nonoverlapping ran-along the portal tracts (score 1). Subsequently, the fibrotic process infiltrates the hepatic parenchyma and dom fields per section, all of which contained the central vein and the portal tracts, was used to generate a single forms bridging septa (linkage) between portal tracts and between portal tracts and the central vein (score 3). Fi-value for each specimen.
nally, the liver architecture is severely compromised. A Nomenclature to Designate Biliary Structures marked collagen accumulation is observed in the interstitial spaces with formation of fibrous septa separating The terminology used in this work to designate biliary structures refers to the consensus on nomenclature and surrounding small nodules of parenchyma: this defines the cirrhosis stage (score 4). Representative photo-of the finer branches of the biliary tree published by Roskams et al., and also applied by other authors to de-micrographs of each fibrosis score, obtained at different times after the BDL procedure in the BDL rat group, are scribe "ductular reaction" and liver fibrosis after BDL (5, 21, 42) . "Ductular reaction" implies a reaction of duc-shown in Figure 1 .
In both experimental groups (BDL and BDL + AM), tular phenotype. In the case of injury caused by obstruction of the common bile duct (BDL model), we will use liver fibrosis became detectable 2 weeks post-BDL procedure and was located around biliary structures of the this term to designate the increasing numbers of biliary structures (ductules) (i.e., cholangiocyte proliferation) portal tracts. Interestingly, although in the control BDL group the fibrosis worsened progressively thereafter, that arise in response to the injury and that are intensely CK19 positive.
reaching the cirrhosis stage at the last time point, in BDL + AM rats the progression of liver fibrosis was less Statistical Analysis severe than that observed in BDL rats. Indeed, in BDL + AM rats, fibrosis remained confined at the portal/peri-Data are reported as median and interquartile range (IQR). Kruskal-Wallis nonparametric analysis of vari-portal areas, with no formation of complete fibrous septal linkage between portal tracts, no fibrotic process in ance was performed to evaluate the statistical significance of the difference among treatment groups. Differ-the interstitial spaces of hepatic parenchyma and, importantly, no cirrhotic lesions were ever observed. ences between treatment groups at the specific time points were then assessed by using the Mann-Whitney Semiquantitative Knodell scoring of these experimental results is reported in Figure 2 . Specifically, at 4 test with Holm-Bonferroni's correction for multiple comparisons. A value of p < 0.05 was considered statis-weeks post-BDL, the median score values were 2.0 (IQR: 2.0) in BDL + AM rats and 3.0 (IQR: 1.0) in BDL tically significant. Data analysis was performed with SPSS for Windows, version 10.0 (SPSS Inc., Chicago, rats (p<0.05). In contrast with BDL rats, which showed a continuous evolution of fibrosis from week 4 to week IL, USA). 6 [from 3.0 (IQR: 1.0) to 4.0 (IQR: 1.0) score units],
RESULTS
BDL + AM rats did not show any further fibrotic progression [the fibrosis median score value remained at The potential role of human AM patches for the treatment of liver fibrosis was investigated in rats subjected 2.0 (IQR: 2.0) at both time points].
Considering that liver fibrotic injury induced by the to the common BDL and scission procedures, a classical experimental method to induce biliary fibrosis in animal BDL procedure is the outcome of a cascade of events and that multiple profibrogenic pathways are activated models and to analyze the events leading from the initial injury of the bile ducts to the organization of a fibrotic in this process, as well as undertaking the semiquantitative evaluation of the fibrotic process, we included in reaction, and, finally, to the outcome of cirrhosis (21) . The level of fibrosis achieved was firstly assessed by our study, as reported below, the quantitative assessment of three main parameters that are specifically involved the classical semiquantitative Knodell fibrosis scoring system (7) , which was applied to the histological exami-in the establishment and progression of such a biliary fibrotic lesion: ductular reaction, myofibroblast activa-ous bile ductules in the periportal areas (Fig. 3A) . Four weeks after BDL, the ductular reaction continued in the tion, and collagen deposition. portal/periportal areas and extended deeply into the he-Human AM Reduced BDL-Induced Ductular Reaction patic lobule (Fig. 3B) . At week 6, the ductular reaction was very intense and delineated complete nodules of he-To evaluate the potential of human AM in reducing the ductular reaction (i.e., the abnormal proliferation of patic parenchyma, with additional CK19-positive small ductules arising within these circumscribed nodules biliary structures) induced by the BDL procedure, we analyzed the expression of CK19, a marker of biliary (Fig. 3C) .
In BDL + AM rats, although the ductular reaction ob-epithelial cells, in the liver tissues of BDL and BDL + AM group rats. served at week 2 was similar to that found in BDL rats, at the later time points it progressed more slowly than In the liver tissues of the BDL group, the ductular reaction progressively and constantly increased from in BDL rats ( Fig. 3D-F) . Intriguingly, at week 6, in contrast to the BDL group, the ductular reaction did not week 2 up to week 6, as can be seen from representative photomicrographs, captured at different time points (Fig. circumscribe any nodules of hepatic parenchyma (Fig. 3F) . The areas occupied by CK19-positive cells were 3A-C). Specifically, at week 2, well-formed biliary structures were observed in the portal tracts and numer-quantitatively evaluated by digital image analysis (Fig. In BDL rats, a progressive increase in α-SMA immunoreactivity was found at all time points analyzed, and cells progressively increases. Indeed, at week 4, this occupied 12.76% (IQR: 7.53) of the liver area ( Fig. 3I) this colocalized with fibrosis (collagen deposition) around biliary structures. At week 2, α-SMA-positive and at week 6 the hepatic parenchyma area involved was almost doubled to 18.82% (IQR: 9.75) ( Fig. 3I ). cells were found mainly in portal tracts (Fig. 4A ). Afterwards, at week 4, α-SMA-positive cells surrounded the In BDL + AM rats at week 4, only 5.91% (IQR: 5.05) of the liver area was involved in ductular reaction (p < reactive bile ductules that formed portal-portal bridges during the progression of fibrosis ( Fig. 4B ) and at week 0.01 vs. BDL group, at the same time point) (Fig. 3I) , and at week 6 it only weakly increased up to 9.45% 6, α-SMA immunoreactivity was also detected around ductules going deeply into the hepatic lobule and into (IQR: 3.85) (p < 0.01 vs. BDL group) ( Fig. 3I ).
perisinusoidal spaces (Fig. 4C ). Human AM Reduced BDL-Induced α-SMA immunoreactivity detected in rats treated Myofibroblast Activation with human AM was lower at all time points with respect to that found in BDL rats. In these rats, α-SMA-Given that α-SMA-positive and therefore activated myofibroblasts are the principal cells responsible for the positive cells were found in the portal and periportal areas and, even at week 6, they were confined to these collagen production and deposition observed in the fibrosis process (58), we assessed the potential of human areas without homogenous distribution around all biliary structures (i.e., not all periductular cells were immuno-AM to reduce myofibroblast activation by monitoring the presence of α-SMA-positive cells in liver samples positive) ( Fig. 4D-F) . The data obtained by the quantitative digital image collected from rats of both experimental groups at different time points after BDL induction.
analysis confirmed a lower presence of activated myofibroblasts in the livers of AM-treated rats with respect to In normal liver, α-SMA immunoreactivity is restricted to the wall of portal veins, hepatic arterioles, and BDL rats ( Fig. 4G-I) . Indeed, at week 2, the liver area occupied by α-SMA-positive cells in the AM-treated AM could serve as a hepatoprotective agent against hepatic damage associated with fibrotic degeneration. rats was only 4.90% (IQR: 4.62) while in BDL rats it was 9.11% (IQR: 3.39) (p < 0.01 vs. BDL group at the Biliary fibrosis and resultant cirrhosis are among the most common outcomes of chronic liver diseases. Un-same time point) ( Fig. 4I) . At week 4, α-SMA-positive cells occupied 9.63% of the liver area (IQR: 7.72) in fortunately, the therapeutic repertoire currently available for treating liver fibrosis and cirrhosis of this type and BDL + AM rats (p < 0.05 vs. BDL group) and 14.87% (IQR: 6.92) in BDL rats (Fig. 4I) . Intriguingly, at week others is very limited and, often, the only effective remaining treatment is orthotopic liver transplantation 6, while in BDL group the liver area occupied by the activated myofibroblasts increased to 21.85% (IQR: (1, 36) . Therefore, strategies to reduce hepatic fibrosis and to avoid the need for organ transplantation are 11.10) ( Fig. 4I) , in the AM-treated rats it was 4.76% (IQR: 3.10) (p < 0.01 vs. BDL group), an area even strongly required. To our knowledge, this is the first study aiming at investigating whether human AM smaller than that occupied at week 4 and similar to that occupied at week 2 (Fig. 4I) .
patches can be used as a possible treatment for biliary fibrosis in an animal model (BDL-treated rat) commonly Human AM Decreased the BDL-Induced used for the study of such a type of fibrosis, and that Collagen Deposition mimics very well the situation of extrahepatic cholestasis arising in a variety of human liver diseases (21, To quantitatively evaluate the effects of human AM on liver collagen deposition, Goldner's modified Mas- 30, 40) . First, we have demonstrated that human AM applica-son trichrome staining-positive areas were analyzed and quantified by image analysis morphometry in liver sam-tion reduces liver fibrosis when evaluated using the classical semiquantitative Knodell scoring system. Indeed, ples collected from rats of both experimental groups. Representative photomicrographs and quantitative data while in the BDL rat group, fibrosis showed a rapid progression leading to cirrhosis within 6 weeks, with colla-collected after 2, 4, and 6 weeks from BDL and BDL + AM rats are shown in Figure 5 .
gen accumulation around ductular structures and in the interstitial spaces, in the BDL + AM rat group the appli-In BDL rats, from week 2 to week 4, liver collagen deposition markedly increased and no further significant cation of human AM was able to confine the fibrosis to the portal/periportal area, with no formation of complete expansion of occupied liver area was observed after week 4 ( Fig. 5A-C) . Furthermore, although collagen de-fibrous septal linkage between portal tracts and no further progression in liver fibrosis after 4 weeks from position observed at week 2 was similar in the two group of animals, afterwards no further progression was BDL.
By conducting an in-depth analysis of the stages that observed in the BDL + AM rats ( Fig. 5D-F) .
The quantitative evaluation by digital image analysis characterize biliary fibrosis induced by the BDL procedure, our results indicate that the application of human confirmed that, at week 2, collagen deposition was comparable in rats of both groups (Fig. 5G-I) but subse-AM inhibits the cascade of events leading to liver fibrosis/cirrhosis in such a model, resulting in a final reduc-quently it was significantly reduced in the AM-treated rats. Indeed, in BDL rats at week 4, the collagen deposi-tion of hepatic fibrosis. Specifically, we have shown that the application of tion area involved 20.61% (IQR: 6.78) of the liver area ( Fig. 5I ) and at week 6, it remained at 18.38% (IQR:
human AM slows the gradual progression of the ductular reaction, to the point that it is significantly reduced 8.29) (Fig. 5I) . In contrast, in BDL + AM rats, liver areas occupied by collagen at week 4 and week 6 were within 6 weeks in BDL + AM rats compared to the BDL rat group. This is a very important finding, considering only 9.92% (IQR: 2.15) and 11.35% (IQR: 1.54), respectively (p < 0.01 vs. BDL group at the same time that the ductular reaction (i.e., cholangiocyte proliferation and increased number of ductules) is one of the first points) (Fig. 5I) .
process triggered by the BDL procedure and is thought DISCUSSION to have a key role in the initiation and progression of liver fibrosis (13,21,41). These results are in line with This study demonstrates that human AM, when applied as a patch onto the liver surface, reduces progres-those reported by Chen et al. (10). Indeed, these authors, using the BDL model to induce liver fibrosis, demon-sion of experimental biliary fibrosis induced in rats by the BDL procedure. Combining a semiquantitative eval-strated that chromium attenuation of liver fibrosis was first evidenced by a reduction in the severity of BDL-uation of the fibrotic process and the quantitative assessment of three main parameters specifically involved in induced ductular reaction. Following ductular proliferation, the chronic obstruc-the establishment and progression of biliary fibrosis (i.e., ductular reaction, myofibroblast activation, and tion of bile duct causes massive activation of myofibroblasts in the periductal region and at the end results collagen deposition), our findings suggest that human in biliary fibrosis/cirrhosis (3, 59) . From this study we also been hypothesized by Tsai et al. (55) to explain the observed reduction in liver fibrosis in the absence of found that human AM reduces the occurrence of α-SMA-expressing cells in the hepatic parenchyma after differentiation of engrafted Wharton's jelly-derived cells, which had been transplanted into rats with carbon BDL induction, and this was already evident 2 weeks after BDL. α-SMA is the histological hallmark of acti-tetrachloride (CCl 4 )-induced liver fibrosis. In addition, we have recently hypothesized such a paracrine mecha-vated myofibroblasts, which secrete large amounts of ECM proteins, including collagen, and increase ECM nism to explain the ability of placenta-derived cells to reduce bleomycin-induced lung fibrosis (9) and of hu-accumulation during fibrosis (58) . Given that, in biliary fibrosis induced by BDL, α-SMA-positive myofi-man AM patches to exert a protective effect against ischemia-induced changes in cardiac functions and dimen-broblasts may originate not only from hepatic stellate cells (HSCs)/residential fibroblasts, but also from the sions (8) . This hypothesis stems from the fact that the AM, as well as cells derived from this tissue, are able bile duct epithelium through epithelial-mesenchymal transition (EMT) (21, 59) , the reduction in the area occu-to release several factors that have potent immunomodulatory, anti-inflammatory, and antiscarring effects (12,50). pied by myofibroblasts could be correlated, at least in part, with the decreased ductular reaction area observed Nevertheless, the identification of the specific paracrine bioactive molecules produced by AM and their tar-in the rat group treated with AM.
Finally, our data suggest that the reduction in ductu-get cells involved in the antifibrotic effects of AM on the liver remains to be explored. Considering that sev-lar proliferation and in myofibroblast activation could participate in the attenuation of the collagen deposition eral studies have suggested that proliferating cholangiocytes have a role in the induction of liver biliary fibrosis, process. Although at 2 weeks after BDL the collagen deposition area was not significantly different in BDL + either directly, via EMT and therefore providing a source of fibrogenic myofibroblasts, or indirectly via activation AM rats compared to the BDL rats, after 4 and 6 weeks, collagen deposition was reduced by about 50% in the of other liver cell types, such as resident portal fibroblasts and HSCs (21), by means of autocrine and para-BDL + AM rats group. These data indicate a novel strategy for reducing collagen deposition in a BDL model of crine mediators, (21, 26, 59) , it is conceivable that one of the targets of the paracrine actions of human AM might biliary fibrosis. Indeed, other studies reported to date using this same experimental model have demonstrated be cholangiocytes. Furthermore, taking into account the fact that the AM can modulate TGF-β1 synthesis and/or reduction of hepatic collagen deposition by means of other therapeutic agents, such as chromium supplemen-signaling pathways (29, 47, 56) , it is possible that the human AM patch might lead to a reduction in the expres-tation (10) and hepatocyte growth factor (14,59).
Taken together, these data indicate that the human sion of profibrogenic factors such as TGF-β1 and PDGF, or proinflammatory cytokines (e.g., IL-1, IL-6, AM does not prevent the formation of fibrosis, but certainly inhibits its progression to the end stage of disease. etc.). To perform an exhaustive assessment of fibrosis and avoid potential confusing findings deriving from in-The exact mechanism whereby human AM exerts these beneficial effects on BDL-induced liver fibrosis complete sampling, our approach called for whole organ resection and formalin fixation, which prevented us remains to be defined, and at present we can only speculate as to the nature of such mechanisms. Because by in from performing expression studies in the livers of our experimental animals. However, it is worth noting that situ hybridization analysis (for human genome-specific ALU-repetitive DNA sequences and human chromo-reduction of TGF-β1 expression has been previously suggested to explain part of the mechanism of fibrosis some 17 centromere) (data not shown) no human cells were detected in the sections of AM-treated rat livers, reduction achieved by other approaches, such as MSC transplantation (25, 55) , HGF administration (59) , and this suggests that, within the limits of these experimental methods, no massive (or at least very low/undetectable) chromium supplementation (10). Nonetheless, direct testing of the potential paracrine engraftment of AM-derived cells occurred in the host liver. Although we cannot exclude the possibility that function of the AM, as well as of other cell types that have been shown to have anti-inflammatory and antifi-few AM-derived cells engrafted in the liver, it is conceivable that the beneficial effects exerted by AM patch brotic effects (11,55), would add mechanistic insights to our findings and clearly warrants further experimenta-application might not be due to a replacement mechanism, in which engrafted AM-derived cells differenti-tions.
Because the same therapeutic approach may exert ated toward the hepatogenic lineage, but that, most likely, the effects observed were associated with the re-different, and even opposite, effects (reduction versus worsening) on fibrogenesis according to the type of fi-lease of soluble factors by cells of the human AM patch (and of the few engrafted cells), which exerted paracrine brosis/cirrhosis (57) , the beneficial effects achieved with the human AM patch on BDL-induced biliary fibrosis effects. This mechanism, based on paracrine effects, has 
